Kraj: Kanada
Język: angielski
Źródło: Health Canada
ERDAFITINIB
JANSSEN INC
L01EN01
ERDAFITINIB
5MG
TABLET
ERDAFITINIB 5MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0161931003; AHFS:
APPROVED
2019-10-25
_Approved Product Monograph 1.docx_ _ _ _ _ _EDMS-RIM-1068395 v13.0 _ _Page 1 of 38 _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR BALVERSA ® Erdafitinib tablets tablet, 3 mg, 4 mg and 5 mg, oral Protein Kinase Inhibitor, (ATC code: L01EN01) BALVERSA ® (erdafitinib), indicated for: • the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), whose tumors have susceptible fibroblast growth factor receptor (FGFR)2 or FGFR3 genetic alterations and who have disease progression during or following at least one line of prior chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for BALVERSA ® please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs- health-products/drug-products/notice-compliance/conditions.html Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada © 2024 Janssen Inc. All trademarks used under license. Date of Initial Authorization: OCT 25, 2019 Date of Revision: FEB 06, 2024 Submission Control Number: 278912 _Approved Product Monograph 1.docx_ _ _ _ _ _EDMS-RIM-1068395 v13.0 _ _Page 2 of 38 _ _ _ NOTICE OF COMPLIANCE WITH CONDITIONS WHAT IS A NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C)? _An NOC/c is a form of market approval granted to a product on the basis of promising _ _evidence of clinical effectiveness following review of the submission by Health Canada. _ _Products authorized under Health Canada’s NOC/c policy are intended for the treatment, _ _prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They _ _have demonstrated promising benefit, are of high quality and possess an acceptable _ _safety profile based on a benefit/risk assessment. In addit Przeczytaj cały dokument